Biopharma's stock market winners of 2022 revealed

In a tough year for biopharma, clear pipeline success was required to end the year on the stock market leaders’ board. Hats off then to the likes of Daiichi Sankyo, Orion, Verona and Madrigal, all of which won substantial share price gains in 2022.

On the flip side, the pandemic players came back to earth after reaching eye-watering highs in 2021. These developers, including Biontech, Moderna and Novavax, dominate the list of stock market losers, with good old-fashioned clinical setbacks claiming a few other names.